Studying gefapixant for cough in kidney or bladder cancer
Part of Lungs & breathing clinical trials.
This study tests a medicine called gefapixant to see if it helps reduce chronic coughing in people with kidney or bladder cancer. You may qualify if your cough persists despite treatment and you have little to no smoking history.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney or bladder cancer (diagnosed at least 8 weeks ago).
- Your cough continues even after treatment for common causes like asthma, acid reflux, or postnasal drip.
- You either never smoked, or you smoked but no more than 20 pack-years (for example, 1 pack a day for 20 years).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests a new radioactive drug (177Lu-FAP-2286) for advanced bladder cancer that has stopped responding to standard treatments. The drug targets a protein on the cancer cells to deliver radiation directly to them, with the goal of shrinking tumors and controlling the disease.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
This trial tests whether combining a special scan (FAPI PET) with a simple blood test (liquid biopsy) can better detect and manage bladder cancer. It aims to improve staging and treatment decisions for patients.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
Hear when a new Chronic Cough trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.